Cohort Follow-up: Progression and Consequences of Chronic Kidney Disease.

NCT04070885 | Completed

• 1 other identifier: CHUBX 2009/29
• Study Type: observational
• Target: 210
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study aims to conduct a prospective collection of clinical and para-clinical data in patients with Chronic Renal Diseases to identify disease progression factors, markers of renal function, and the pathophysiology of Chronic Renal Diseases complications.

Conditions

Chronic Renal Diseases; Renal Function Disorder

Outcome Measures

Primary Outcomes (4)

• Estimated Glomerular Filtration Rate measurement

  by isotope technique

  At 1 year after inclusion

• Estimated Glomerular Filtration Rate measurement

  by isotope technique

  At 2 year after inclusion

• Measured Glomerular Filtration Rate

  by isotope technique

  At 1 year after inclusion

• Measured Glomerular Filtration Rate

  by isotope technique

  At 2 years after inclusion

Interventions

Blood sample PROCEDURE

A dry tube of 7 ml of blood, two 4 ml EDTA tubes, a 4 ml heparinized tube and an 8.5 ml ACD-A tube will be collected from the patient.

Urine sample PROCEDURE

The urine will be taken from three 15 ml tubes.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The participation in NephroTest will be offered to eligible patients by the doctors of the Nephrology Department, during consultations or as a result of hospitalization.

You may qualify if:

• Patients with Chronic Renal Disease, stage 2 to 5, non-dialysis patients over the age of 18,
• followed in the Nephrology Department of the Bordeaux University Hospital
• agreeing to participate in NephroTest
• affiliated with social security.

You may not qualify if:

• Patients under 18 years
• Patients with acute or rapidly progressive renal failure
• Patients with severe comorbidities or comorbidities that are life-threatening in the short term (\<1 year)
• Patients who did not give their written consent to be included in the study
• Major incapacitated patients and psychiatric patients admitted to hospital

Sponsors & Collaborators

• University Hospital, Bordeaux: lead

Biospecimen

Retention: SAMPLES WITHOUT DNA

A dry tube of 7 ml of blood, two 4 ml ethylene-diamine-tetra-acetic acid tubes, a 4 ml heparinized tube and an 8.5 ml citrate dextrose acid tube will be collected from the patient. The urine will be taken from three 15 ml tubes.

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Study Officials

• Christian COMBE, Pr

  University Hospital, Bordeaux

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 22, 2019
• First Posted: August 28, 2019
• Study Start: January 5, 2011
• Primary Completion: March 20, 2015
• Study Completion: March 20, 2015
• Last Updated: August 28, 2019

Record last verified: 2019-08